Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Camostat Mesylate (DWJ1248) in Healthy Volunteers
NCT04782505Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Mar 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of camostat mesilate in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration of GBPA and Area Under the Curve to Last Measurable Concentration of GBPA. Started Mar 2021; status: completed.
02
Drugs
camostat mesilate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04782505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04782505.